← Pharmacy curriculum
Module 586 lessonsPituitary Society consensus and current US labeling

Pituitary Pharmacology

Connect hypothalamic and pituitary signaling to biochemical diagnosis, tumor behavior, hormone excess, hormone deficiency, water balance, and product-specific pharmacotherapy.

01

Map hypothalamic signals, pituitary cell types, target glands, feedback loops, pulsatility, and mass effects.

02

Diagnose and treat acromegaly using IGF-1, clinical context, surgery, somatostatin receptor ligands, pegvisomant, and selected dopamine agonist therapy.

03

Evaluate hyperprolactinemia and prolactinoma, then use cabergoline safely across tumor, fertility, pregnancy, and psychiatric contexts.

04

Replace deficient pituitary axes in the correct sequence with laboratory targets that match central rather than primary endocrine disease.

05

Diagnose arginine vasopressin deficiency and use desmopressin without causing water intoxication or masking postoperative physiology.

06

Recognize pituitary apoplexy, visual compromise, postoperative water disorders, and other situations requiring urgent multidisciplinary care.

58.01

Axis Physiology and Pituitary Assessment

Pituitary reasoning begins with an axis map. Hormone concentration, target-gland response, feedback, timing, tumor size, and visual anatomy must be interpreted together.

What to learn
  • Hypothalamic signals
  • Anterior and posterior pituitary
  • Feedback and pulsatility
  • Hormone excess and deficiency
  • Mass effect and visual fields
Endocrine controlRead every result as an axis, not an isolated number
01HypothalamusRelease or restraint

CRH, TRH, GnRH, GHRH, somatostatin, and dopamine

02PituitarySignal and pulse

ACTH, TSH, LH, FSH, GH, prolactin, and posterior release

03TargetHormone and feedback

Cortisol, thyroid hormone, gonadal steroids, IGF-1, and water balance

Map each functional axis

CRH drives ACTH and cortisol, TRH supports TSH and thyroid hormone, GnRH pulses regulate LH and FSH, and GHRH and somatostatin balance GH and IGF-1. Hypothalamic dopamine tonically restrains prolactin. Arginine vasopressin and oxytocin are synthesized in hypothalamic nuclei and released from posterior pituitary terminals. A sellar lesion can therefore cause hormone excess, deficiency, or both.

Interpret patterns instead of isolated values

Pituitary hormones can be pulsatile, circadian, stress responsive, sex and age dependent, or altered by pregnancy, illness, nutrition, kidney function, and medication. Central deficiency may present with a target hormone that is low while the pituitary hormone is low or inappropriately normal. A result within the laboratory range can still be physiologically inappropriate.

Evaluate the whole gland and the surrounding anatomy

A pituitary mass assessment includes symptoms of hormone excess and deficiency, prolactin and IGF-1, adrenal and thyroid axes, gonadal function when relevant, pregnancy context, medication review, dedicated MRI, and formal visual fields when the optic apparatus is threatened. Headache, diplopia, sudden visual loss, altered mental status, or hemodynamic instability changes the timeline.

Protect the adrenal axis first

When central adrenal insufficiency and central hypothyroidism may coexist, establish glucocorticoid coverage before starting or increasing levothyroxine. Thyroid hormone can increase cortisol clearance and metabolic demand and may precipitate adrenal crisis. Dynamic testing, timing, acute illness, exogenous corticosteroids, and assay interference must be considered before declaring an axis intact.

0 of 1 answered
01Which pattern best supports central hypothyroidism?
Answer every question to submit.
58.02

Acromegaly Diagnosis and Pharmacotherapy

Growth hormone excess drives IGF-1, progressive tissue overgrowth, metabolic disease, sleep apnea, cardiovascular burden, arthropathy, and tumor effects. Treatment controls both biochemistry and the tumor.

What to learn
  • IGF-1 and diagnosis
  • Transsphenoidal surgery
  • Somatostatin receptor ligands
  • GH receptor antagonism
  • Monitoring and comorbidity
GH and IGF-1Control secretion, action, tumor, and systemic disease
01ResectExpert surgery

Remove resectable tumor and decompress threatened anatomy

02SuppressSomatostatin receptors

Injectable or oral ligands lower GH with product-specific use

03BlockGH receptor

Pegvisomant lowers IGF-1 despite persistent GH secretion

Use IGF-1 in clinical context

In a patient with typical features, the 2024 consensus supports IGF-1 above 1.3 times the age-adjusted upper limit of normal as confirming acromegaly. Repeat equivocal IGF-1 with the same validated assay and consider an oral glucose tolerance test when uncertainty remains. Random GH can inform prognosis but is not required for diagnosis. MRI follows biochemical evidence rather than replacing it.

Place surgery at the center of resectable disease

Experienced transsphenoidal surgery is generally first treatment for a resectable GH-secreting pituitary tumor and can decompress the optic apparatus while offering remission. Residual or unresectable disease can require repeat surgery, medical therapy, radiation, or combinations. Follow IGF-1, tumor imaging, symptoms, and systemic complications over time.

Suppress secretion through somatostatin receptors

Octreotide and lanreotide primarily use SSTR2 signaling to reduce GH. Pasireotide has broader receptor binding, including strong SSTR5 activity, but carries substantial dysglycemia risk. Oral octreotide capsules are maintenance therapy for patients who responded to and tolerated octreotide or lanreotide and require strict empty-stomach administration. Paltusotine is an oral nonpeptide SSTR2 agonist for adults with inadequate surgical response or when surgery is not an option, with its own fasting and interaction instructions.

Block action when secretion remains uncontrolled

Pegvisomant antagonizes the GH receptor and is titrated to age-adjusted IGF-1, not GH, because some GH assays cross-react and GH remains elevated. Monitor liver tests, injection sites, glucose-lowering needs, and residual tumor by imaging. Cabergoline can lower GH in selected mild disease but is off label for acromegaly in the United States. Treatment success includes comorbidity control, not a laboratory value alone.

0 of 1 answered
01Which laboratory value should guide pegvisomant dose titration?
Answer every question to submit.
58.03

Hyperprolactinemia and Prolactinoma

Prolactin rises from autonomous secretion, stalk disruption, medication, pregnancy, hypothyroidism, kidney disease, or assay effects. The cause determines whether dopamine agonist therapy is appropriate.

What to learn
  • Dopamine and lactotrophs
  • Differential diagnosis
  • Macroprolactin and hook effect
  • Cabergoline
  • Surgery, fertility, and pregnancy
Dopamine restraintExplain the elevation before treating the prolactin
01ConfirmResult and context

Pregnancy, stress, macroprolactin, dilution, and assay fit

02ExcludeSecondary causes

Medication, hypothyroidism, kidney disease, and stalk effect

03TreatD2 receptor

Cabergoline lowers secretion and usually reduces tumor volume

Start with dopamine physiology and a broad differential

Tuberoinfundibular dopamine activates lactotroph D2 receptors and suppresses prolactin release. Pregnancy and lactation, stress, sleep, chest-wall stimulation, primary hypothyroidism, kidney or liver disease, stalk compression, and many antipsychotic, antiemetic, antidepressant, opioid, estrogen, and other drugs can increase prolactin. Repeat an unexpected result under appropriate conditions and obtain a pregnancy test when relevant.

Resolve laboratory and imaging discordance

Macroprolactin can produce a laboratory elevation with limited bioactivity, while the high-dose hook effect can artifactually lower a very high prolactin result in a large tumor. Ask the laboratory for macroprolactin evaluation or serial dilution when the phenotype, value, and mass do not agree. Stalk effect usually produces a different biochemical context from a large secreting prolactinoma.

Use cabergoline as the preferred dopamine agonist

Cabergoline is a long-acting ergot-derived D2 agonist that usually lowers prolactin, restores gonadal function, and shrinks tumor. Start low, titrate to prolactin and tumor response, and monitor nausea, orthostasis, headache, psychiatric symptoms, impulse-control effects, and dose-related valvular risk. The 2023 consensus also supports discussing expert surgery for selected well-circumscribed lesions rather than presenting lifelong medication as the only option.

Plan withdrawal, fertility, and pregnancy deliberately

A carefully selected patient with sustained biochemical control and marked tumor reduction may attempt dopamine agonist withdrawal with follow-up. Fertility can return before menses normalize. Pregnancy planning depends on tumor size, invasion, symptoms, prior surgery, and treatment response. Most routine prolactin measurements are not useful during pregnancy, while new headache or visual symptoms require urgent assessment.

0 of 1 answered
01What should be considered when a very large sellar mass is paired with only a modest prolactin elevation?
Answer every question to submit.
58.04

Hypopituitarism and Hormone Replacement

Replacement follows physiologic priority rather than a fixed list. Cortisol safety comes first, while each central deficiency requires a target that does not depend on a failing pituitary signal.

What to learn
  • Central adrenal insufficiency
  • Central hypothyroidism
  • Central hypogonadism
  • Growth hormone deficiency
  • Sequence and reassessment
Replacement sequenceProtect the essential axis before optimizing the others
01FirstCortisol safety

Glucocorticoid coverage and emergency stress planning

02ThenTarget-gland hormone

Free T4, sex steroids, fertility therapy, and clinical goals

03RevisitDynamic pituitary state

Retest after surgery, tumor response, radiation, and illness

Make glucocorticoid safety the first priority

Central adrenal insufficiency can cause fatigue, weight loss, nausea, hypoglycemia, hyponatremia, hypotension, and crisis, often without the hyperkalemia expected in primary adrenal failure because aldosterone is usually preserved. Use physiologic hydrocortisone or an equivalent regimen, teach sick-day dosing and emergency injection, and give stress doses for major illness or surgery.

Target free T4 in central hypothyroidism

Levothyroxine treats central hypothyroidism, but TSH cannot be used as the dose target. After glucocorticoid sufficiency is established, titrate using free T4, symptoms, age, cardiac risk, pregnancy context, adherence, and interactions. A suppressed TSH can be expected and does not independently prove overtreatment in central disease.

Individualize gonadal and growth hormone replacement

Central hypogonadism requires sex, age, fertility goals, pregnancy potential, bone health, thrombosis risk, cancer history, and patient preference. Gonadotropins or pulsatile GnRH may be needed for fertility rather than sex steroid replacement alone. Adult GH deficiency requires validated testing in context and cautious dose titration to clinical response and age-adjusted IGF-1, with attention to edema, arthralgia, carpal tunnel symptoms, glucose, and contraindications.

Reassess axes as the anatomy changes

Surgery, radiation, apoplexy, tumor growth, and effective tumor treatment can create, reveal, or reverse deficiencies. Reassess all relevant axes after pituitary surgery and periodically after radiation or major tumor response. Medication reconciliation must include exogenous glucocorticoids, opioids, antiepileptics, estrogen route, supplements, and agents that alter thyroid-binding proteins or hormone metabolism.

0 of 1 answered
01Which replacement should generally be established first when central adrenal insufficiency and central hypothyroidism coexist?
Answer every question to submit.
58.05

Arginine Vasopressin Deficiency and Desmopressin

Arginine vasopressin deficiency causes hypotonic polyuria and compensatory thirst. Desmopressin restores antidiuresis but can cause dangerous hyponatremia when intake exceeds renal water excretion.

What to learn
  • Water-balance physiology
  • Diagnostic differentiation
  • Desmopressin routes
  • Hyponatremia prevention
  • Postoperative water disorders
Water balanceReplace antidiuresis without trapping excess free water
01ProveHypotonic polyuria

Measure urine volume and concentration and exclude solute diuresis

02ReplaceV2-selective signal

Use product-specific desmopressin dose, route, and timing

03ReleasePermit aquaresis

Monitor sodium and allow retained water to clear when appropriate

Trace water balance from osmolality to aquaporin

Hypothalamic osmoreceptors and baroreceptors regulate arginine vasopressin release. V2 receptor signaling in the collecting duct inserts aquaporin-2 channels and concentrates urine. Deficiency produces high-volume dilute urine, rising serum osmolality or sodium when water access is limited, and intense thirst when the thirst mechanism is intact.

Prove hypotonic polyuria before naming the disorder

Quantify urine volume and urine osmolality, then exclude hyperglycemia, osmotic diuresis, diuretics, hypercalcemia, hypokalemia, kidney disease, and excess intake. Water deprivation and desmopressin testing or stimulated copeptin can distinguish arginine vasopressin deficiency, renal resistance, and primary polydipsia in specialized settings. Never perform water deprivation casually in a patient who cannot maintain hydration.

Treat with product-specific desmopressin

Desmopressin is a V2-selective analogue available in several formulations with different potency, absorption, indications, and dose units. Routes are not directly interchangeable. Individualize timing around nocturia, daytime function, residual secretion, thirst, kidney function, and the ability to drink. Allow periodic breakthrough urination when appropriate so retained free water can be excreted.

Prevent water intoxication

Excess fluid intake during sustained antidiuresis can cause weight gain, headache, nausea, confusion, seizure, coma, or respiratory arrest from hyponatremia. Teach fluid guidance, symptom recognition, sodium monitoring, and temporary interruption during vomiting, diarrhea, fever, extreme heat, vigorous exercise, or other conditions that disrupt fluid balance. Postoperative patients can transition from transient deficiency to SIADH and back again, so fixed early dosing can be hazardous.

0 of 1 answered
01What is the most important preventable danger of excessive desmopressin effect combined with high fluid intake?
Answer every question to submit.
58.06

Sellar Emergencies, Surgery, and Longitudinal Safety

Pituitary care can change from chronic endocrine management to a neurologic and hemodynamic emergency. Visual compromise, apoplexy, adrenal failure, and postoperative water shifts demand coordinated action.

What to learn
  • Pituitary apoplexy
  • Visual compromise
  • Perioperative hormones
  • Postoperative monitoring
  • Longitudinal tumor and axis care
Sellar urgencyVision, perfusion, cortisol, and sodium define the emergency
01DetectApoplexy or compression

Sudden headache, visual loss, ophthalmoplegia, and instability

02ProtectCortisol and anatomy

Stress-dose steroid and urgent multidisciplinary evaluation

03FollowPostoperative transitions

Urine, sodium, vision, imaging, and every pituitary axis

Recognize pituitary apoplexy

Acute hemorrhage or infarction in a pituitary lesion can cause sudden severe headache, visual field loss, reduced acuity, ophthalmoplegia, meningismus, altered consciousness, and acute ACTH deficiency. Obtain urgent endocrine, neurosurgical, ophthalmologic, and imaging evaluation. Give stress-dose glucocorticoid promptly when adrenal insufficiency or hemodynamic instability is suspected.

Use anatomy and function to determine urgency

Formal visual fields are required when a lesion abuts or compresses the optic apparatus. Progressive visual deficit, neurological compromise, apoplexy with visual disturbance, or selected hypersecreting tumors can require surgery. Prolactinoma is a major exception because dopamine agonist therapy can rapidly reduce prolactin and tumor volume in many patients.

Monitor the postoperative sequence

Track cortisol, free T4, sodium, urine volume, urine concentration, thirst, intake, and neurological status. Early arginine vasopressin deficiency can resolve, be followed by delayed SIADH, and occasionally recur. Avoid automatic scheduled desmopressin during unstable early physiology. Reassess pituitary axes beginning around six weeks after surgery and periodically thereafter.

Build a lifelong surveillance record

Record tumor type, pathology, residual anatomy, visual findings, surgery, radiation, medical therapy, hormone excess, deficiencies, replacement doses, emergency education, fertility and pregnancy plans, bone and metabolic health, and imaging schedule. Radiation-related deficiencies can emerge years later, while effective therapy can restore some axes and alter replacement needs.

0 of 1 answered
01Which action is most urgent when pituitary apoplexy causes hemodynamic instability and possible ACTH deficiency?
Answer every question to submit.

Check the connections.

Each attempt draws 10 questions from the complete 100 question bank.

100 questions in this module bank10 questions per attempt

Each attempt draws a fresh set and rearranges the answer choices.

Current clinical foundation.

Lecture material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.

  1. 2024 consensus on acromegaly diagnosis and remission
  2. 2023 Pituitary Society prolactinoma consensus
  3. Endocrine Society hypopituitarism guideline
  4. FDA Palsonify prescribing information
  5. FDA Somavert prescribing information
  6. FDA Desmoda prescribing information
PharmacyOpen tools